Vi­ral man­u­fac­tur­er Viba­log­ics plots out ex­pan­sion at Ger­man site as US growth plans are un­der­way

A Ger­man CD­MO spe­cial­iz­ing in vi­ral man­u­fac­tur­ing is ex­pand­ing its op­er­a­tions in Eu­rope by build­ing out an ex­ist­ing plant — and soon, it will be its own land­lord, too.

Viba­log­ics has be­gun the first stage of a $50 mil­lion ex­pan­sion of its Cux­haven, Ger­many fa­cil­i­ty, the com­pa­ny an­nounced. It will al­so buy the site out­right from the cur­rent own­er.

The CD­MO spe­cial­izes in the pro­duc­tion of on­colyt­ic virus­es and vi­ral vec­tor-based vac­cines and gene ther­a­py prod­ucts. The ex­pan­sion will add an­oth­er 100,000 square feet at the site for qual­i­ty batch re­lease and sta­bil­i­ty stud­ies, drug prod­uct fill-fin­ish and process de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER